Trial Profile
A phase I/II trial of upamostat in combination with chemotherapy in patients with resected pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 31 Aug 2017
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2017 According to a RedHill Biopharma media release, this trial is execpted to initiate in the first half of 2018.
- 28 Feb 2017 New trial record
- 23 Feb 2017 According to a RedHill Biopharma media release, this trial is execpted to initiate in the second half of 2017.